United-Guardian Inc (UG) FinancialsUGUnited-Guardian Inc

United-Guardian Inc (UG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharmaceutical, accounting for 47.2% of total sales, equivalent to $1.47M. Other significant revenue streams include Cosmetic Ingredients and Medical. Understanding this composition is critical for investors evaluating how UG navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, United-Guardian Inc maintains a gross margin of 49.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.26%, while the net margin is 23.44%. These profitability ratios, combined with a Return on Equity (ROE) of 21.35%, provide a clear picture of how effectively UG converts its operational activities into shareholder value.

In the context of the broader market, UG competes directly with industry leaders such as EXOZ and HTOO. With a market capitalization of $31.12M, it holds a significant position in the sector. When comparing efficiency, UG's gross margin of 49.73% stands against EXOZ's N/A and HTOO's 12.36%. Such benchmarking helps identify whether United-Guardian Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue and net income, with a recent net income of $728,579 for Q2 2026, but a significant drop in revenue of 13.5% year-over-year raises concerns about sustainability.